Intellectual Property Protection in the EU Pharmaceutical Industry and Global Access to Medicines

Elsun Elvarovich Guseinov and Tatiana Mikhailovna Isachenko
Additional contact information
Elsun Elvarovich Guseinov: MGIMO University, Moscow, Russia
Tatiana Mikhailovna Isachenko: MGIMO University, Moscow, Russia

Russian Foreign Economic Journal, 2025, issue 09, 25-41

Abstract: The article provides a comprehensive analysis of the European Union’s trade policy in the pharmaceutical sector, exploring its dual impact on the global market. It examines the dialectical contradiction between the objectives of stimulating pharmaceutical innovation through enhanced intellectual property (IP) protection and ensuring global access to medicines. Based on an analysis of the TRIPS Agreement and EU regulatory instruments, including “TRIPS-plus” provisions, the EU’s strategy of exporting its normative model is identified. A quantitative analysis of trade flows and a case study of EU-India trade relations demonstrate the practical consequences of this policy.

Keywords: trade policy; European Union; intellectual property; pharmaceuticals; TRIPS Agreement; access to medicines; international trade; WTO; developing countries (search for similar items in EconPapers)
JEL-codes: F10 (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://repec.vavt.ru/RePEc/alq/rufejo/rfej_2025_09_25-41.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:alq:rufejo:rfej_2025_09_25-41

DOI: 10.64545/2072-8042-2025-9-25-41

Access Statistics for this article

More articles in Russian Foreign Economic Journal from Russian Foreign Trade Academy Ministry of economic development of the Russian Federation Contact information at EDIRC.
Bibliographic data for series maintained by Irina Katolik ().